TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07805759: Clinical Investigation of Daydrop® Triple Action for the Symptomatic Treatment of Allergic Conjunctivitis.

Sponsor: i+Med S.Coop. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 49 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,624,000

Rescue Site Savings

+$7,005,200

Unlock Full NCT07805759 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07805759 Rescue Dossier →